Slide 1: Orion Interim Report Q1─Q3/2012
Orion Interim Report Q1─Q3/2012 23 October 2012 Timo Lappalainen President and CEO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of these strat
Slide 3: Sales developed well
Sales developed well • Net sales grew despite decline in sales of Parkinson’s drugs as anticipated – Sales of other products up by 11% • Operating profit at similar level to comparative period • Research projects progressed as planned – Positive results from Phase II of ODM-101 project (Parkinson’s
Slide 4: Net sales and operating profit
Net sales and operating profit Group key figures Q1─Q3/2012 Q1─Q3/2011 Change % 2011 Net sales, EUR million 726 682 +7% 918 Operating profit, EUR million 222 223 -1% 283 Basic earnings per share, EUR 1.18 1.17 +1% 1.49 Cash flow per share before financial items, EUR 0.92 0.77 +19% 1.10 • Net sales u
Slide 5: Breakdown of net sales
Breakdown of net sales By business divisions By market area Proprietary Products Specialty Products Finland Scandinavia Other Europe Animal Health Fermion North America Other Countries Contract manufacturing & Other Orion Diagnostica Sales 16% 4% 6% through partners 28% 5% 26% 7% 41% 13% 13% 37% 32%
Slide 6: Business Reviews
Business Reviews
Slide 7: Specialty Products maintained strong growth
Specialty Products maintained strong growth Key figures for Pharmaceuticals business Q1─Q3/2012 Q1─Q3/2011 Change % 2011 Net sales of Pharmaceuticals, EUR million 687 647 +6% 871 Proprietary Products 300 306 -2% 409 Specialty Products 270 238 +13% 321 Animal Health 52 49 +7% 68 Fermion 36 32 +16% 43
Slide 8: Best-selling pharmaceuticals
Best-selling pharmaceuticals Orion’s best-selling pharmaceuticals, EUR million Q1─Q3/2012 Q1─Q3/2011 Change % 2011 1. Stalevo®, Comtess® and Comtan® (Parkinson’s disease) 192 202 -5% 267 2. Simdax® (acute decompensated heart failure) 32 31 +3% 44 3. Precedex® (intensive care sedative) 28 22 +27% 33
Slide 9: Orion clear market leader in Finland
Orion clear market leader in Finland Finnish human pharmaceuticals Finland’s biggest pharmaceutical market in Q1─Q3/2012 companies in Q1─Q3/2012 • Wholesale EUR 1,489 million (+2%) EUR million 180 162 160 Orion in Finnish human pharmaceuticals market 140 • Sales growth 8% 120 • Orion clear market le
Slide 10: Sales of Parkinson's drugs growing in Japan
Sales of Parkinson’s drugs growing in Japan Overall markets for Parkinson’s drugs Market shares of entacapone MAT6 MAT6 July 2011─June 2012 drugs 2012 2011 • United States 3) USD 679 million (-11%) Finland 2) 25% 23% Sweden 2) 14% 15% • Five largest European markets 1) 3) EUR 952 million (-6%) Norwa
Slide 11: Precedex still growing strongly
Precedex still growing strongly Markets for intensive care sedative Breakdown of Precedex Precedex July 2011─June 2012 markets USD million 200 180 • Total USD 230 million (+27%) 160 140 • United States USD 178 million 120 (+22%) 100 80 60 40 20 0 USA Other countries Source: IMS Health sales statisti
Slide 12: Key clinical pharmaceutical development projects
Key clinical pharmaceutical development projects Clinical phases Project Indication I II III Registration Easyhaler® combined formulations Asthma, COPD Stalevo® for Japanese markets 1) Parkinson’s disease ODM-101 Parkinson’s disease (more effective levodopa product) ODM-201 2) Advanced prostate canc
Slide 13: Net sales grew in Diagnostics business
Net sales grew in Diagnostics business Key figures for Diagnostics business Q1─Q3/2012 Q1─Q3/2011 Change % 2011 Net sales, EUR million 41 37 +12% 50 Operating profit, EUR million 3.1 4.2 -27% 4.9 • QuikRead® tests remained main product – Sales of more user-friendly prefilled QuikRead 101 system and
Slide 14: Outlook for 2012
Outlook for 2012 (updated on 9 October) • Net sales will be slightly higher than in 2011 • Operating profit will be at similar level to 2011 • Group’s capital expenditure about EUR 50 million excluding substantial corporate or product acquisitions 14 23 October 2012 Orion Interim Report Q1─Q3/2012
Slide 15: Orion Calendar
Orion Calendar • Financial Statements 2012 5 February 2013 • Annual General Meeting 2013 19 March 2013 • Interim Report January─March 2013 23 April 2013 • Interim Report January─June 2013 30 July 2013 • Interim Report January─September 2013 22 October 2013 • The Annual Report 2012 will be published
Slide 16: Slide 16
Slide 17: Orion's financial objectives
Orion’s financial objectives Orion’s financial objectives are: • Ensuring financial stability • Profitable growth The objectives are achieved through: • Increasing net sales. Achievement of this objective requires continuous investment in development of the product portfolio. • Maintaining profitabi
Slide 18: Key figures by quarter
Key figures by quarter EUR million Net sales EUR million Operating profit 1000 300 283 918 900 850 254 222 772 726 60 250 800 711 236 53 215 207 700 193 200 185 Q4 65 Q4 600 180 246 44 76 211 33 71 500 213 Q3 150 Q3 192 56 170 44 65 400 Q2 66 Q2 227 233 100 60 300 196 207 45 50 181 Q1 Q1 200 50 93 7
Slide 19: Key figures for 2008─Q3/2012
Key figures for 2008─Q3/2012 Orion’s key figures 2008 2009 2010 2011 Q1─Q3/2012 Q1─Q3/2011 Change % Net sales, EUR million 710.7 771.5 849.9 917.9 726.0 681.8 +6.5% Operating profit, EUR million 185.0 207.0 254.2 282.9 221.5 223.4 -0.8% Profit before taxes, EUR million 184.2 203.7 252.6 282.0 220.5
Slide 20: Development of sales of own proprietary products
Development of sales of own proprietary products Net sales of proprietary products, EUR million Indication Q1─Q3/2012 Q1─Q3/2011 Change % 2011 Stalevo®, Comtess® and Comtan® Parkinson’s disease 192.2 202.4 -5.0% 266.7 Acute decompensated Simdax® 32.1 31.3 +2.6% 44.0 heart failure Intensive care Prec
Slide 21: Income Statement 2008─Q3/2012
Income Statement 2008─Q3/2012 Formation of profits, EUR million 2008 2009 2010 2011 Q1-Q3/2012 Q1-Q3/2011 Change % Net sales 710.7 771.5 849.9 917.9 726.0 681.8 +6.5% Cost of goods sold -243.4 -265.2 -283.2 -305.1 -253.7 -219.8 +15.4% Gross profit 467.4 506.3 566.8 612.8 472.2 462.0 +2.2% Other oper
Slide 22: Orion's main research programmes
Orion’s main research programmes • Expansion of Easyhaler® product family. Under development are new budesonide-formoterol and fluticasone-salmeterol combined formulations for treatment of asthma and COPD. • Orion and Novartis are developing Parkinson’s drug Stalevo® for Japanese markets. – Novartis
Slide 23: Product protection situation of key products
Product protection situation of key products Key patents or data protection expire Molecule Product Indication Europe USA Japan Stalevo®, November 2012 Entacapone Parkinson’s disease October 2013 2) 2015 3) Comtess® and Comtan® October 2013 1) Acute Levosimendan Simdax® decompensated September 2015
Slide 24: Dividend distribution policy
Dividend distribution policy Dividend distribution history Dividend distribution policy EUR 1.40 140% 1.20 120% Orion’s dividend distribution takes into account distributable funds and capital 1.00 100% expenditure and other financial 0.80 80% requirements in medium and long term to achieve the fina
Slide 25: Slide 25